{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:42Z","timestamp":1778591442065,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009540","name":"Frank A. Campini Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2 TR001870"],"award-info":[{"award-number":["KL2 TR001870"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32CA128583"],"award-info":[{"award-number":["5T32CA128583"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bbmt.2019.06.006","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T02:51:09Z","timestamp":1560307869000},"page":"2031-2039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Vanessa P.","family":"Tolbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Dvorak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Golden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Vissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nura","family":"El-Haj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-2499","authenticated-orcid":false,"given":"Katherine K.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieuhoa T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.06.006_bib0001","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0003","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0004","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(05)70291-6","article-title":"Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial","volume":"6","author":"Berthold","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41416-018-0169-8","article-title":"Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation","volume":"119","author":"Berthold","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0007","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/pbc.20219","article-title":"High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group","volume":"44","author":"Pritchard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0008","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bmt.2012.276","article-title":"A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1","volume":"48","author":"Seif","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0009","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.2000.18.13.2567","article-title":"Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma","volume":"18","author":"Grupp","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA3","article-title":"A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): a Children's Oncology Group (COG) study","volume":"34","author":"Park","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/bmt.2017.207","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies","volume":"53","author":"Khosla","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.blre.2012.05.001","article-title":"Thrombotic complications associated with stem cell transplantation","volume":"26","author":"Nadir","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0016","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0017","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0018","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0019","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: opening Pandora's box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0022","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0023","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0024","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0025","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/j.bbmt.2016.12.462","article-title":"Thrombotic microangiopathy (TMA) and organ injury after autologous transplant is higher with carboplatin\/etoposide\/melphalan (CEM) compared with either busulfan and melphaln or cyclophosphamide and thiotepa in patients with neuroblastoma","volume":"23","author":"Jodele","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0026","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose carboplatin\/etoposide\/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0027","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0028","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study","volume":"29","author":"Park","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0029","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approach to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.2005.03.6400","article-title":"Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approach to neuroblastoma therapy consortium study","volume":"24","author":"Matthay","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0031","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/pbc.25994","article-title":"A phase I new approach to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent\/refractory high-risk neuroblastoma","volume":"63","author":"Villablanca","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0032","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0033","article-title":"A safety and feasibility study of 131I-MIBG in newly diagnosed high-risk neuroblastoma: a Children's Oncology Group (COG) pilot","author":"Weiss","year":"2018","journal-title":"Adv Neuroblast"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0034","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704733","article-title":"Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation","volume":"34","author":"Woywodt","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0036","article-title":"Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma","author":"Schechter","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0037","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0038","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2017.05.013","article-title":"Acquired complement regulatory gene mutations and hematopoietic stem cell transplant-related thrombotic microangiopathy","volume":"23","author":"Ardissino","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0039","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2017.76.4662","article-title":"Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation","volume":"36","author":"Rachakonda","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.06.006_bib0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/bmt.2015.161","article-title":"The potential role of HLA-DRB1\u00d711 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"50","author":"Balassa","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119303702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119303702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:24:00Z","timestamp":1778588640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119303702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1083879119303702"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.006","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}